Etanercept for Crohn's Disease

Publisher Website
Google Scholar
Abstract
I would like to correct an error in the Perspective by Kupper (Nov. 20 issue)1 on immunologic targets in psoriasis. Dr. Kupper indicated that etanercept (Enbrel), a tumor necrosis factor α (TNF-α)–receptor fusion protein, has demonstrated efficacy in inflammatory bowel disease. In fact, in the most authoritative published experience with etanercept in the treatment of inflammatory bowel disease (a randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Crohn's disease), the drug was shown to be ineffective,2 and it does not have marketing approval for any indication in inflammatory bowel disease.